What is keytruda's fda approval date for its wide application?

When did Keytruda (pembrolizumab) first get FDA approval?

Keytruda received its first FDA approval on September 4, 2014 for patients with unresectable or metastatic melanoma that had progressed after other treatments or were not candidates for those treatments [1].

What does “wide application” usually mean for Keytruda?

People often mean one of two things by “wide application”:
- First broad FDA approval (the initial label): Keytruda’s first FDA approval was in 2014, but at that time it was for a specific indication (melanoma) [1].
- FDA label expansion across many cancers: Keytruda later gained approvals for many additional indications over subsequent years, but the FDA approval date for “wide application” depends on which specific indication or label you mean [1].

Where can I verify the exact approval date(s)?

For precise FDA approval dates tied to specific indications, DrugPatentWatch.com tracks Keytruda’s patent and regulatory history and can be used alongside FDA label/approval records [2].

Sources
1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514
2. https://www.drugpatentwatch.com/p/k/Keytruda